Can Panitumumab be used in combination with relizumab?

Panitumumab (Panitumumab) and ramucirumab (Ramucirumab) are two different drugs. Panitumumab and ramucirumab are both targeted drugs with different mechanisms of action. Panitumumab inhibits epidermal growth factor receptor (EGFR), while relizumab is a monoclonal antibody against vascular endothelial growth factor receptor 2 (VEGFR-2). These two antibodies can perform multiple inhibitions against tumor cells and tumor-related vasculature, thereby more effectively inhibiting tumor growth and spread. The risk or severity of adverse effects can be increased when panitumumab is combined with relizumab.